OREANDA-NEWS. Russian-Japanese Healthcare Business Forum was held in Tokyo on April 15-16, 2013. The forum was aimed to expand collaboration between Russian and Japanese healthcare and pharmaceutical industries. The event attracted over 300 leading scientists, experts and businessmen. The Business Forum was organized by All-Russia Business Association “Delovaya Rossiya” (“Business Russia”) and The Japan Association for Trade with Russia & NIS (ROTOBO). Russian delegation was led by A. Likhachev, Russian Deputy Minister of Economic Development, accompanied by representatives of “Delovaya Rossiya”, Russian Ministry of Economic Development, Russian Healthcare Ministry, The Skolkovo Foundation, Rosatom and leading Russian companies – R-Pharm, Acrikhin, Electron etc.

Alexey Repik, Chairman of the Board “R-Pharm”, took part in the Russian-Japanese Medical Forum “Future of private and public healthcare partnerships” and two round table discussions – “Pharmaceutical and biotech industries” and “Medical services and equipment”. Alexey Repik highlighted the fact that focus of Russian-Japanese cooperation is shifting from energy and commodities towards high-tech innovative technologies. Also he declared key priorities of “Delovaya Rossiya”: “We’re interested in high-tech industries cooperation development able to support science and education. Successful development in modern globalized world requires international technology and knowledge exchange, cooperation and expansion of international business collaboration. You can see new industrial plants opening in Russia. The country’s real economy demonstrates the growth that opens new areas for investment cooperation. R-Pharm and other members of “Delovaya Rossiya” demonstrate viability of long-term investment projects in Russia and reliability of cooperation with Russian partners. Our success proves that Russia is a promising investment area.” Also Alexey Repik named life sciences among the most promising fields for Russian-Japanese cooperation.

Participating in round tables Alexey Repik presented the successful cases of international pharmaceutical projects. He shared his personal experience of private-public partnership and highlighted its important role in development of diagnostics technologies, conduction of clinical and pre-clinical trials, training of skilled pharmaceutical professionals and establishing of pharmaceutical and medical clusters. “We are very optimistic about this partnership. Collaboration between Japanese and Russian high-tech companies supports the accessibility of innovative healthcare techniques for Russian patients,” said Mr. Repik.

Mr. Repik also paid attention to the importance of social mission performed by companies participating in private-public partnership. This mission includes the establishing of training and internship programs for gifted Russian students and young scientists: “Education and recurrent training programs are always very important for us. Collaboration between our countries looks very promising in terms of educational opportunities.”

Russian and Japanese organizations signed several agreements during the Forum: “We’re doing a very important job for the benefits of both Russian and Japanese parties. We receive active feedback from our Japanese partners, both current and potential, and this is very important for all Russian companies,” said Alexey Repik.